Uterine and Adnexa Procedures DRG 740 Reimbursement Guide

DRG 740 addresses inpatient uterine and adnexa procedures for non-ovarian and non-adnexal malignancy when a Complication or Comorbidity is present; it defines the clinical scope and case mix for payment. Correct specification of procedures and Complication or Comorbidity documentation matters for inpatient reimbursement under Centers for Medicare & Medicaid Services rules.

DRG 740 Overview

DRG 740 covers inpatient admissions for uterine and adnexa surgical procedures performed for non-ovarian and non-adnexal malignancy when the record includes a documented Complication or Comorbidity. This Diagnosis-Related Group is focused on procedures such as hysterectomy and related resection of uterine or fallopian tube structures where a Complication or Comorbidity increases clinical complexity. It matters for Medicare payment because the presence of a Complication or Comorbidity shifts resource intensity and reimbursement relative to cases without such comorbid conditions. Accurate coding of the principal procedure and all relevant diagnoses determines appropriate Medicare Severity Diagnosis-Related Group assignment and payment.

DRG 740 Overview

Perioperative multimodal management trials comparing surgical approaches and enhanced recovery protocols for patients undergoing hysterectomy or adnexal surgery for uterine or other non-ovarian non-adnexal malignancies with significant comorbidity. These studies enroll hospitalized adults who require uterine or adnexal procedures and have complicating conditions (e.g., obesity, diabetes, cardiopulmonary disease) classified as complications or comorbidities (CC), and they test interventions such as minimally invasive versus open surgery pathways, anesthesia/analgesia bundles, and standardized perioperative care pathways. Results inform clinicians on reducing length of stay, complication rates, and resource use, and help payers evaluate which perioperative strategies are cost-effective for this higher-acuity DRG group.
Comparative effectiveness studies of adjuvant therapy sequencing and intraoperative decision tools for patients with uterine or other non-ovarian non-adnexal malignancy who require additional staging or cytoreductive procedures identified during the index admission. These trials or observational comparative cohorts focus on whether immediate extended surgery, staged procedures, or early initiation of adjuvant therapy impacts short-term surgical outcomes, readmission, and downstream oncologic outcomes for patients with CCs that increase perioperative risk. Findings are relevant to providers weighing operative extent against morbidity and to payers assessing downstream costs from readmissions, additional procedures, and long-term treatment pathways tied to decisions made during the inpatient episode.
Post-discharge outcomes and health services research tracking complications, functional recovery, and healthcare utilization in the 30–90 days after discharge for patients in this DRG, especially those with CC-driven increased risk of wound infection, thromboembolism, or hospital readmission. These prospective registries or pragmatic studies evaluate predictors of readmission, the effectiveness of transitional care interventions (telehealth follow-up, home health nursing, anticoagulation management), and total episode-of-care costs for this higher-acuity surgical cohort. Data guide hospitals and payers on targeted risk-reduction strategies, resource allocation for post-acute care, and reimbursement models that account for elevated post-discharge utilization in this group.

Perioperative multimodal management trials comparing surgical approaches and enhanced recovery protocols for patients undergoing hysterectomy or adnexal surgery for uterine or other non-ovarian non-adnexal malignancies with significant comorbidity. These studies enroll hospitalized adults who require uterine or adnexal procedures and have complicating conditions (e.g., obesity, diabetes, cardiopulmonary disease) classified as complications or comorbidities (CC), and they test interventions such as minimally invasive versus open surgery pathways, anesthesia/analgesia bundles, and standardized perioperative care pathways. Results inform clinicians on reducing length of stay, complication rates, and resource use, and help payers evaluate which perioperative strategies are cost-effective for this higher-acuity DRG group.
Comparative effectiveness studies of adjuvant therapy sequencing and intraoperative decision tools for patients with uterine or other non-ovarian non-adnexal malignancy who require additional staging or cytoreductive procedures identified during the index admission. These trials or observational comparative cohorts focus on whether immediate extended surgery, staged procedures, or early initiation of adjuvant therapy impacts short-term surgical outcomes, readmission, and downstream oncologic outcomes for patients with CCs that increase perioperative risk. Findings are relevant to providers weighing operative extent against morbidity and to payers assessing downstream costs from readmissions, additional procedures, and long-term treatment pathways tied to decisions made during the inpatient episode.
Post-discharge outcomes and health services research tracking complications, functional recovery, and healthcare utilization in the 30–90 days after discharge for patients in this DRG, especially those with CC-driven increased risk of wound infection, thromboembolism, or hospital readmission. These prospective registries or pragmatic studies evaluate predictors of readmission, the effectiveness of transitional care interventions (telehealth follow-up, home health nursing, anticoagulation management), and total episode-of-care costs for this higher-acuity surgical cohort. Data guide hospitals and payers on targeted risk-reduction strategies, resource allocation for post-acute care, and reimbursement models that account for elevated post-discharge utilization in this group.

OpenPayer

Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

Sign up for Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview policy alerts

DRG 740 Overview

Catch payer policy changes before they impact reimbursement

Catch payer policy changes before they impact reimbursement

OpenPayer

Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

Sign up for Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview policy alerts

DRG 740 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References